menu
    • menu

    Company profile for Xeltis

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Xeltis is a developer of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device comprises bioabsorbable heart valves and blood vessels designed to allow endogenous tissue restoration which is the natural restoration of the complex body part that gets replaced upon implantation, enabling the patient's body to naturally restore a new blood vessel or heart valve through a therap...
    Xeltis is a developer of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device comprises bioabsorbable heart valves and blood vessels designed to allow endogenous tissue restoration which is the natural restoration of the complex body part that gets replaced upon implantation, enabling the patient's body to naturally restore a new blood vessel or heart valve through a therapeutic approach.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    XeltisNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    DE LISMORTEL 31 5612 AR EINDHOVEN
    Telephone
    Telephone
    +31 407517614
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://xeltis.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/xeltis/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Xeltis?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Xeltis Secures €50M from EIB, Shareholders for Axess Launch
    Xeltis Secures €50M from EIB, Shareholders for Axess Launch

    02 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xeltis-secures-nearly-50m-from-the-european-investment-bank-eib-and-existing-shareholders-to-advance-axess-its-vascular-access-conduit-to-the-market-302629421.html

    PR NEWSWIRE
    02 Dec 2025
    Share Share
    Xeltis Eyes Commercialization After Positive aXess Trial Results
    Xeltis Eyes Commercialization After Positive aXess Trial Results

    24 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xeltis-poised-for-commercialization-following-excellent-clinical-data-from-axess-eu-pivotal-multicentre-trial-302565604.html

    PR NEWSWIRE
    24 Sep 2025
    Share Share
    Xeltis Reports Positive Data for Xabg in EU Clinical Trial
    Xeltis Reports Positive Data for Xabg in EU Clinical Trial

    17 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xeltis-announces-positive-data-for-xabg-its-coronary-artery-bypass-conduit-in-eu-clinical-trial-302507014.html

    PR NEWSWIRE
    17 Jul 2025
    Share Share
    Xeltis passes evaluation for €10M investment from European Council
    Xeltis passes evaluation for €10M investment from European Council

    08 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xeltis-successfully-passes-evaluation-phase-for-10million-investment-from-european-innovation-council-302422154.html

    PR NEWSWIRE
    08 Apr 2025
    Share Share
    Xeltis adds experts in Clinical Nephrology to Medical Board
    Xeltis adds experts in Clinical Nephrology to Medical Board

    11 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xeltis-expands-medical-advisory-board-with-world-leading-experts-in-clinical-nephrology-302397441.html

    PR NEWSWIRE
    11 Mar 2025
    Share Share
    Xeltis Completes Enrollment In EU Trial For aXess Market Approval
    Xeltis Completes Enrollment In EU Trial For aXess Market Approval

    07 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xeltis-announces-completion-of-enrolment-in-eu-pivotal-trial-for-axess-and-prepares-for-market-approval-302343306.html

    PR NEWSWIRE
    07 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search